Last: | $0.914 |
---|---|
Change Percent: | 0.94% |
Open: | $0.98 |
Close: | $0.914 |
High: | $0.98 |
Low: | $0.9 |
Volume: | 359,976 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.914 | $0.98 | $0.914 | $0.98 | $0.9 | 359,976 | 07-02-2024 |
$0.9893 | $1.03 | $0.9893 | $1.09 | $0.9134 | 433,502 | 07-01-2024 |
$1 | $1.16 | $1 | $1.16 | $1 | 4,721,857 | 06-28-2024 |
$1.14 | $1.15 | $1.14 | $1.17 | $1.11 | 379,846 | 06-27-2024 |
$1.15 | $1.26 | $1.15 | $1.27 | $1.15 | 313,807 | 06-26-2024 |
$1.24 | $1.22 | $1.24 | $1.24 | $1.2 | 716,593 | 06-25-2024 |
$1.24 | $1.18 | $1.24 | $1.27 | $1.18 | 222,065 | 06-24-2024 |
$1.19 | $1.2 | $1.19 | $1.225 | $1.165 | 313,235 | 06-21-2024 |
$1.2 | $1.19 | $1.2 | $1.21 | $1.16 | 135,467 | 06-20-2024 |
$1.2 | $1.18 | $1.2 | $1.27 | $1.1704 | 230,256 | 06-19-2024 |
$1.2 | $1.18 | $1.2 | $1.27 | $1.1704 | 230,256 | 06-18-2024 |
$1.17 | $1.15 | $1.17 | $1.18 | $1.11 | 336,145 | 06-17-2024 |
$1.15 | $1.22 | $1.15 | $1.22 | $1.11 | 353,797 | 06-14-2024 |
$1.2 | $1.27 | $1.2 | $1.27 | $1.18 | 341,918 | 06-13-2024 |
$1.26 | $1.29 | $1.26 | $1.3 | $1.24 | 242,123 | 06-12-2024 |
$1.25 | $1.29 | $1.25 | $1.32 | $1.225 | 266,865 | 06-11-2024 |
$1.3 | $1.2 | $1.3 | $1.3 | $1.2 | 243,345 | 06-10-2024 |
$1.225 | $1.25 | $1.225 | $1.26 | $1.22 | 137,257 | 06-07-2024 |
$1.265 | $1.29 | $1.265 | $1.3 | $1.17 | 362,370 | 06-06-2024 |
$1.31 | $1.33 | $1.31 | $1.36 | $1.29 | 178,795 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...